Provenge News

erisian
Member Posts: 107
http://www.zerocancer.org/site/News2?page=NewsArticle&id=11424
Updated Survival Data on Provenge for Treatment of Hormone Refractory Prostate Cancer Presented
"These data confirm the survival advantage of Provenge over placebo for men with hormone-refractory prostate cancer. It is anticipated that these findings will result in FDA approval of Provenge."
Let's hope so.
Updated Survival Data on Provenge for Treatment of Hormone Refractory Prostate Cancer Presented
"These data confirm the survival advantage of Provenge over placebo for men with hormone-refractory prostate cancer. It is anticipated that these findings will result in FDA approval of Provenge."
Let's hope so.
0
Comments
-
More info
"...PROVENGE increased three-year survival by 40 percent compared to placebo (32.1 percent vs 23.0 percent), the median survival difference of PROVENGE compared to placebo was maintained at 4.1 months, with a 24.1 percent reduction in the risk of death..."
Here are a couple of links on the subject:
Dendreon press release:
http://tinyurl.com/Provenge-PR
PDF of presentation on the IMPACT study given at ASCO-GU conference:
http://tinyurl.com/Provenge-pdf0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 122.3K Cancer specific
- 2.8K Anal Cancer
- 451 Bladder Cancer
- 310 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 399 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 677 Leukemia
- 799 Liver Cancer
- 4.2K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 240 Multiple Myeloma
- 7.2K Ovarian Cancer
- 65 Pancreatic Cancer
- 492 Peritoneal Cancer
- 5.6K Prostate Cancer
- 1.2K Rare and Other Cancers
- 544 Sarcoma
- 740 Skin Cancer
- 658 Stomach Cancer
- 192 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards